1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Multiple Sclerosis - 5EU Drug Forecast and Market Analysis to 2024

Multiple Sclerosis - 5EU Drug Forecast and Market Analysis to 2024

  • September 2015
  • 246 pages
  • ID: 4188642
In this report:
THE MARKET SHARE OF ORAL DMTS IS EXPECTED TO GROW CONSIDERABLY OVER THE FORECAST PERIOD AT A CAGR OF ##.##% TO $##.## BILLION IN 2024, REPRESENTING ##.##% OF THE ##EU MARKET.
TOGETHER, THESE SEVEN PRODUCTS ARE EXPECTED TO GENERATE SALES OF $##.## BILLION IN 2024, REPRESENTING A ##.##% SHARE OF THE TOTAL ##EU MS MARKET.
HOWEVER, THE GLOBAL SALES OF COPAXONE ARE EXPECTED TO DECREASE FROM APPROXIMATELY $##.## BILLION IN 2014 TO $##.## BILLION IN 2024 AT A NEGATIVE CAGR OF ##.##%.

Summary

Table of Contents

Search Inside

Multiple Sclerosis - 5EU Drug Forecast and Market Analysis to 2024

Brief

Multiple Sclerosis is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an appealing phase, with an upsurge of available treatment options. Over the forecast period, patients are anticipated to continue to switch to the oral disease-modifying therapies, lessening the stronghold of the established injectable treatments. There are also different encouraging products in the late-stage pipeline, with a different range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a serious unmet need. These factors are anticipated to increase treatment rates throughout the 10MM resulting, driving market increase. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

GlobalData believes market increase will be steady between 2014 and 2021, driven by an increase in treatment rates as pipeline agents enter the sector. Following this, increase is anticipated to slow as Gilenya faces patent expiry in this sector. The impact of generic competition will be meaningful, as Gilenya is anticipated to be the highest-selling DMT in the 5EU prior to its patent expiry. Market increase driven by the continued uptake of the pipeline agents will be largely offset by Gilenya's generic erosion, and the availability of generic fingolimod will limit the uptake of the novel S1P receptor modulators.

Overview

- Overview of MS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the challenging landscape.

- Exhaustive information on the top drugs in 5EU including product MScription, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the best drugs in 5EU from 2014-2024.

- Analysis of the impact of main events as well the drivers and restraints affecting 5EU MS market.

Great reasons to purchase

- Understand and capitalize by identifying products that are most likely to ensure a strong return

- Stay ahead of the competition by understanding the changing ambitious landscape for MS.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most favorable sales plausible

- Make more informed business decisions from insightful and detailed analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in 5EU.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026SummaryDry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, ...

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027SummaryFor nearly two decades, the Cytomegalovirus (CMV) therapeutics landscape has been dominated by ganciclovir and valganciclovir, with ...

Gene Therapy in Oncology

Gene Therapy in Oncology

  • $ 7995
  • Industry report
  • June 2018
  • by GlobalData

Gene Therapy in OncologySummaryGene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient. The material to be transferred may consist ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on